Splenic marginal zone lymphoma pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(26 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Splenic marginal zone lymphoma}}
{{Splenic marginal zone lymphoma}}
{{CMG}}; {{AE}} {{AS}}
{{CMG}}; {{AE}}{{Affan}}, {{AS}}
==Overview==
==Overview==
Genes involved in the pathogenesis of splenic marginal zone lymphoma include [[immunoglobulin]] genes , 7q21-32, and CDK6 gene. On microscopic histopathological analysis, [[B-cells]], villous lymphocytes, and [[sinus]] invasion are characteristic findings of splenic marginal zone lymphoma.
The exact pathogenesis of [[splenic marginal zone lymphoma]] ([[SMZL]]) is not clearly understood but according to some studies chronic immunologic stimulation and certain [[gene]] [[mutations]] are assumed to be involved. The common [[chromosomal]] aberrations and genetic mutations in [[splenic marginal zone lymphoma]] ([[SMZL]]) includes 7q32 deletion, gain of function [[mutation]] in 3q and  [[NOTCH2]], [[TP53]], [[KLF2]] [[gene]] [[mutations]]. These [[genes]] control certain [[cell regulation]] pathways that are involved in normal functioning of the cell. [[Hepatitis C]] viral antigen has also been assumed to be involved in its pathogenesis. [[Spleen]], [[bone marrow]], [[lymph nodes]], liver and [[blood]] may be infiltrated with the tumor and have certain distintive features. On microscopic histopathological analysis, [[B-cells]], villous [[lymphocytes]], and [[sinus]] invasion are characteristic findings of [[splenic marginal zone lymphoma]] ([[SMZL]]).
==Genetics==
==Pathophysiology==
Genes involved in the pathogenesis of splenic marginal zone lymphoma include:
===Pathogenesis===  
* Clonal rearrangements of the [[immunoglobulin]] genes (heavy and light chains) <ref name="dun1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9635678&query_hl=24&itool=pubmed_ExternalLink]
* Several studies suggest that both chronic immunologic stimulation and gained [[genetic]] [[mutations]]  play a role in the pathogenesis of [[splenic marginal zone lymphoma]] ([[SMZL]]) but the exact mechanism is still not clear.<ref name="pmid26294727">{{cite journal |vauthors=Fonte E, Agathangelidis A, Reverberi D, Ntoufa S, Scarfò L, Ranghetti P, Cutrona G, Tedeschi A, Xochelli A, Caligaris-Cappio F, Ponzoni M, Belessi C, Davis Z, Piris MA, Oscier D, Ghia P, Stamatopoulos K, Muzio M |title=Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation |journal=Haematologica |volume=100 |issue=11 |pages=1460–8 |date=November 2015 |pmid=26294727 |pmc=4825289 |doi=10.3324/haematol.2014.119933 |url=}}</ref><ref name="pmid24452203">{{cite journal |vauthors=Franco G, Guarnotta C, Frossi B, Piccaluga PP, Boveri E, Gulino A, Fuligni F, Rigoni A, Porcasi R, Buffa S, Betto E, Florena AM, Franco V, Iannitto E, Arcaini L, Pileri SA, Pucillo C, Colombo MP, Sangaletti S, Tripodo C |title=Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma |journal=Blood |volume=123 |issue=12 |pages=1836–49 |date=March 2014 |pmid=24452203 |doi=10.1182/blood-2013-04-497271 |url=}}</ref>
* There has been data to suggest that [[splenic marginal zone lymphoma]] ([[SMZL]]) can either originate from pre-germinal center [[B-cells]] or germinal or post-germinal center [[B cells]] based on [[immunoglobulin heavy chain]] [[gene]] [[mutation]].<ref name="pmid9635678">{{cite journal |vauthors=Dunn-Walters DK, Boursier L, Spencer J, Isaacson PG |title=Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation |journal=Hum. Pathol. |volume=29 |issue=6 |pages=585–93 |date=June 1998 |pmid=9635678 |doi= |url=}}</ref><ref name="pmid10088550">{{cite journal |vauthors=Miranda RN, Cousar JB, Hammer RD, Collins RD, Vnencak-Jones CL |title=Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy cell leukemia are composed of memory B lymphocytes |journal=Hum. Pathol. |volume=30 |issue=3 |pages=306–12 |date=March 1999 |pmid=10088550 |doi= |url=}}</ref><ref name="pmid9516137">{{cite journal |vauthors=Tierens A, Delabie J, Pittaluga S, Driessen A, DeWolf-Peeters C |title=Mutation analysis of the rearranged immunoglobulin heavy chain genes of marginal zone cell lymphomas indicates an origin from different marginal zone B lymphocyte subsets |journal=Blood |volume=91 |issue=7 |pages=2381–6 |date=April 1998 |pmid=9516137 |doi= |url=}}</ref><ref name="pmid11688461">{{cite journal |vauthors=Camacho FI, Mollejo M, Mateo MS, Algara P, Navas C, Hernández JM, Santoja C, Solé F, Sánchez-Beato M, Piris MA |title=Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases |journal=Am. J. Surg. Pathol. |volume=25 |issue=10 |pages=1268–76 |date=October 2001 |pmid=11688461 |doi= |url=}}</ref><ref name="pmid9602369">{{cite journal |vauthors=Stevenson F, Sahota S, Zhu D, Ottensmeier C, Chapman C, Oscier D, Hamblin T |title=Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes |journal=Immunol. Rev. |volume=162 |issue= |pages=247–59 |date=April 1998 |pmid=9602369 |doi= |url=}}</ref><ref name="pmid21300984">{{cite journal |vauthors=Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES |title=The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications |journal=Blood |volume=117 |issue=19 |pages=5019–32 |date=May 2011 |pmid=21300984 |pmc=3109529 |doi=10.1182/blood-2011-01-293050 |url=}}</ref>
* Normal [[splenic]] [[marginal zone]] appears to be composed of both naïve and [[memory]] [[B-cells]] which actually support the idea of having different cell origin.<ref name="pmid9745206">{{cite journal |vauthors=Spencer J, Perry ME, Dunn-Walters DK |title=Human marginal-zone B cells |journal=Immunol. Today |volume=19 |issue=9 |pages=421–6 |date=September 1998 |pmid=9745206 |doi= |url=}}</ref><ref name="pmid3898859">{{cite journal |vauthors=Timens W, Poppema S |title=Lymphocyte compartments in human spleen. An immunohistologic study in normal spleens and uninvolved spleens in Hodgkin's disease |journal=Am. J. Pathol. |volume=120 |issue=3 |pages=443–54 |date=September 1985 |pmid=3898859 |pmc=1887979 |doi= |url=}}</ref>
===Genetics===
* [[Clonal rearrangements]] of the [[immunoglobulin]] genes (heavy and light chains) <ref name="dun1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9635678&query_hl=24&itool=pubmed_ExternalLink]
Dunn-Walters DK, Boursier L, Spencer J, Isaacson PG. "Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation." '''Hum Pathol'''. 1998 Jun;29(6):585-93. PMID: 9635678</ref>  
Dunn-Walters DK, Boursier L, Spencer J, Isaacson PG. "Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation." '''Hum Pathol'''. 1998 Jun;29(6):585-93. PMID: 9635678</ref>  
* Deletion 7q21-32 is seen in 40% of SMZL patients
* Most common [[chromosomal]] abnormality seen in [[splenic marginal zone lymphoma]] is the deletion of 7q region.<ref name="pmid14681321">{{cite journal |vauthors=Boonstra R, Bosga-Bouwer A, van Imhoff GW, Krause V, Palmer M, Coupland RW, Dabbagh L, van den Berg E, van den Berg A, Poppema S |title=Splenic marginal zone lymphomas presenting with splenomegaly and typical immunophenotype are characterized by allelic loss in 7q31-32 |journal=Mod. Pathol. |volume=16 |issue=12 |pages=1210–7 |date=December 2003 |pmid=14681321 |doi=10.1097/01.MP.0000095895.19756.77 |url=}}</ref>
* Translocations of the CDK6 gene  located at 7q21 have also been reported<ref name="cor1">
*Other abnormalities such as gain of function [[mutation]] in 3q, 4q, 5q, 9q, 12q, 20q and loss of function mutations in 7q and 17p have also been found.<ref name="pmid11337382">{{cite journal |vauthors=Hernández JM, García JL, Gutiérrez NC, Mollejo M, Martínez-Climent JA, Flores T, González MB, Piris MA, San Miguel JF |title=Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics |journal=Am. J. Pathol. |volume=158 |issue=5 |pages=1843–50 |date=May 2001 |pmid=11337382 |pmc=1891967 |doi=10.1016/S0002-9440(10)64140-5 |url=}}</ref><ref name="pmid15642391">{{cite journal |vauthors=Andersen CL, Gruszka-Westwood A, Atkinson S, Matutes E, Catovsky D, Pedersen RK, Pedersen BB, Pulczynski S, Hokland P, Jacobsen E, Koch J |title=Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization |journal=Cancer Genet. Cytogenet. |volume=156 |issue=2 |pages=122–8 |date=January 2005 |pmid=15642391 |doi=10.1016/j.cancergencyto.2004.04.026 |url=}}</ref><ref name="pmid20479288">{{cite journal |vauthors=Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luño E, Wlodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Solé F |title=Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group |journal=Blood |volume=116 |issue=9 |pages=1479–88 |date=September 2010 |pmid=20479288 |doi=10.1182/blood-2010-02-267476 |url=}}</ref>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10597225&query_hl=28&itool=pubmed_ExternalLink]
* Most common [[genetic]] [[mutation]] is of [[NOTCH2]] [[gene]].<ref name="pmid22891273">{{cite journal |vauthors=Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G |title=The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development |journal=J. Exp. Med. |volume=209 |issue=9 |pages=1537–51 |date=August 2012 |pmid=22891273 |doi=10.1084/jem.20120904 |url=}}</ref><ref name="pmid18508802">{{cite journal |vauthors=Trøen G, Wlodarska I, Warsame A, Hernández Llodrà S, De Wolf-Peeters C, Delabie J |title=NOTCH2 mutations in marginal zone lymphoma |journal=Haematologica |volume=93 |issue=7 |pages=1107–9 |date=July 2008 |pmid=18508802 |doi=10.3324/haematol.11635 |url=}}</ref>
Corcoran MM, Mould SJ, Orchard JA, Ibbotson RE, Chapman RM, Boright AP, Platt C, Tsui LC, Scherer SW, Oscier DG. "Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations." '''Oncogene'''. 1999 Nov 4;18(46):6271-7. PMID: 10597225</ref>
* Other genes involved with decreasing frequency are [[KLF2]], CARD1, [[TRAF3]], [[MYD88]],[[TP53]].<ref name="pmid25283840">{{cite journal |vauthors=Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Bruscaggin A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri SA, Foà R, Inghirami G, Gaidano G, Rossi D |title=The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma |journal=Leukemia |volume=29 |issue=2 |pages=503–7 |date=February 2015 |pmid=25283840 |doi=10.1038/leu.2014.294 |url=}}</ref><ref name="pmid21881048">{{cite journal |vauthors=Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Bruscaggin A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I, Pileri SA, Foà R, Bertoni F, Dalla-Favera R, Pasqualucci L, Gaidano G |title=Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma |journal=Blood |volume=118 |issue=18 |pages=4930–4 |date=November 2011 |pmid=21881048 |doi=10.1182/blood-2011-06-359166 |url=}}</ref><ref name="pmid27503810">{{cite journal |vauthors=Spina V, Rossi D |title=NF-κB deregulation in splenic marginal zone lymphoma |journal=Semin. Cancer Biol. |volume=39 |issue= |pages=61–7 |date=August 2016 |pmid=27503810 |doi=10.1016/j.semcancer.2016.08.002 |url=}}</ref><ref name="pmid8018922">{{cite journal |vauthors=Baldini L, Fracchiolla NS, Cro LM, Trecca D, Romitti L, Polli E, Maiolo AT, Neri A |title=Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin |journal=Blood |volume=84 |issue=1 |pages=270–8 |date=July 1994 |pmid=8018922 |doi= |url=}}</ref><ref name="pmid11369650">{{cite journal |vauthors=Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D |title=p53 abnormalities in splenic lymphoma with villous lymphocytes |journal=Blood |volume=97 |issue=11 |pages=3552–8 |date=June 2001 |pmid=11369650 |doi= |url=}}</ref>
===Immunophenotype===
* Translocations of the [[CDK6]] gene  located at 7q21 have also been reported<ref name="cor1">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10597225&query_hl=28&itool=pubmed_ExternalLink]
Corcoran MM, Mould SJ, Orchard JA, Ibbotson RE, Chapman RM, Boright AP, Platt C, Tsui LC, Scherer SW, Oscier DG. "Dysregulation of cyclin dependent kinase 6 expression in [[splenic marginal zone lymphoma]] through chromosome 7q translocations." '''Oncogene'''. 1999 Nov 4;18(46):6271-7. PMID: 10597225</ref>
 
* There are several pathways involved in the normal functioning of the cells. [[Genetic]] dysregulation may affect these pathways resulting in abnormal function.
* Common [[genetic]] abnormalities and their affected pathways in [[splenic marginal zone lymphoma]] are summarized under:
{| style="border: 0px; font-size: 90%; margin: 3px; width: 400px"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 400px"
|valign=top|
| valign="top" |
|+
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Antigen'''}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Pathways'''}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Splenic marginal zone lymphoma'''}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Gene mutations'''}}
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
[[CD20]]
NFkB<ref name="pmid25428260">{{cite journal |vauthors=Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G, Bolli N, Grove C, Moody S, Escudero-Ibarz L, Gundem G, Brugger K, Xue X, Mi E, Bench A, Scott M, Liu H, Follows G, Robles EF, Martinez-Climent JA, Oscier D, Watkins AJ, Du MQ |title=KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype |journal=Leukemia |volume=29 |issue=5 |pages=1177–85 |date=May 2015 |pmid=25428260 |doi=10.1038/leu.2014.330 |url=}}</ref><ref name="pmid25779943">{{cite journal |vauthors=Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, Parker H, Parker A, Davis Z, Gardiner A, McIver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, de Castro DG, Dearden C, Pratt G, Rosenquist R, Ashton-Key M, Forconi F, Collins A, Ghia P, Matutes E, Pangalis G, Stamatopoulos K, Oscier D, Strefford JC |title=Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing |journal=Clin. Cancer Res. |volume=21 |issue=18 |pages=4174–4183 |date=September 2015 |pmid=25779943 |pmc=4490180 |doi=10.1158/1078-0432.CCR-14-2759 |url=}}</ref><ref name="pmid21881048">{{cite journal |vauthors=Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Bruscaggin A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I, Pileri SA, Foà R, Bertoni F, Dalla-Favera R, Pasqualucci L, Gaidano G |title=Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma |journal=Blood |volume=118 |issue=18 |pages=4930–4 |date=November 2011 |pmid=21881048 |doi=10.1182/blood-2011-06-359166 |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" align=center |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
''' Positive'''
* [[KLF2]], [[TNFAIP3]], [[MYD88]], [[TRAF3]], [[CARD11]], [[MLL2]], [[BTK]], [[REL]], SYK
|-  
|-  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
[[CD79a]]
[[Apoptosis]]<ref name="pmid15914563">{{cite journal |vauthors=Ruiz-Ballesteros E, Mollejo M, Rodriguez A, Camacho FI, Algara P, Martinez N, Pollán M, Sanchez-Aguilera A, Menarguez J, Campo E, Martinez P, Mateo M, Piris MA |title=Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis |journal=Blood |volume=106 |issue=5 |pages=1831–8 |date=September 2005 |pmid=15914563 |doi=10.1182/blood-2004-10-3898 |url=}}</ref><ref name="pmid15507668">{{cite journal |vauthors=Trøen G, Nygaard V, Jenssen TK, Ikonomou IM, Tierens A, Matutes E, Gruszka-Westwood A, Catovsky D, Myklebost O, Lauritzsen G, Hovig E, Delabie J |title=Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma |journal=J Mol Diagn |volume=6 |issue=4 |pages=297–307 |date=November 2004 |pmid=15507668 |pmc=1867488 |doi=10.1016/S1525-1578(10)60525-9 |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" align=center |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
''' Positive'''
* BIRC3, TNFRSF5, [[TRAF3]], [[TRAF5]], [[BTK]], [[XPB]], APAF-1, [[IRF5]], [[REL]], PKCA, TMEM209
|-  
|-  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
[[CD5]]
Cell communication<ref name="pmid24349473">{{cite journal |vauthors=Parry M, Rose-Zerilli MJ, Gibson J, Ennis S, Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier DG, Strefford JC |title=Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma |journal=PLoS ONE |volume=8 |issue=12 |pages=e83244 |date=2013 |pmid=24349473 |pmc=3862727 |doi=10.1371/journal.pone.0083244 |url=}}</ref><ref name="pmid22816737">{{cite journal |vauthors=Fresquet V, Robles EF, Parker A, Martinez-Useros J, Mena M, Malumbres R, Agirre X, Catarino S, Arteta D, Osaba L, Mollejo M, Hernandez-Rivas JM, Calasanz MJ, Daibata M, Dyer MJ, Prosper F, Vizcarra E, Piris MÁ, Oscier D, Martinez-Climent JA |title=High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma |journal=Br. J. Haematol. |volume=158 |issue=6 |pages=712–26 |date=September 2012 |pmid=22816737 |doi=10.1111/j.1365-2141.2012.09226.x |url=}}</ref><ref name="pmid24296945">{{cite journal |vauthors=Martínez N, Almaraz C, Vaqué JP, Varela I, Derdak S, Beltran S, Mollejo M, Campos-Martin Y, Agueda L, Rinaldi A, Kwee I, Gut M, Blanc J, Oscier D, Strefford JC, Martinez-Lopez J, Salar A, Sole F, Rodriguez-Peralto JL, Diez-Tascón C, García JF, Fraga M, Sebastián E, Alvés J, Menárguez J, González-Carreró J, Casado LF, Bayes M, Bertoni F, Gut I, Piris MA |title=Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation |journal=Leukemia |volume=28 |issue=6 |pages=1334–40 |date=June 2014 |pmid=24296945 |doi=10.1038/leu.2013.365 |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" align=center |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
'''Negative'''
* [[MS4A2]], TOSO, [[LPXN]], [[PTPRC]], [[PTPN1]], [[BTK]], [[LCP1]]
|-  
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
[[CD10]]
[[Cell cycle control]]<ref name="pmid20479288">{{cite journal |vauthors=Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luño E, Wlodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Solé F |title=Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group |journal=Blood |volume=116 |issue=9 |pages=1479–88 |date=September 2010 |pmid=20479288 |doi=10.1182/blood-2010-02-267476 |url=}}</ref><ref name="pmid15507668">{{cite journal |vauthors=Trøen G, Nygaard V, Jenssen TK, Ikonomou IM, Tierens A, Matutes E, Gruszka-Westwood A, Catovsky D, Myklebost O, Lauritzsen G, Hovig E, Delabie J |title=Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma |journal=J Mol Diagn |volume=6 |issue=4 |pages=297–307 |date=November 2004 |pmid=15507668 |pmc=1867488 |doi=10.1016/S1525-1578(10)60525-9 |url=}}</ref><ref name="pmid24296945">{{cite journal |vauthors=Martínez N, Almaraz C, Vaqué JP, Varela I, Derdak S, Beltran S, Mollejo M, Campos-Martin Y, Agueda L, Rinaldi A, Kwee I, Gut M, Blanc J, Oscier D, Strefford JC, Martinez-Lopez J, Salar A, Sole F, Rodriguez-Peralto JL, Diez-Tascón C, García JF, Fraga M, Sebastián E, Alvés J, Menárguez J, González-Carreró J, Casado LF, Bayes M, Bertoni F, Gut I, Piris MA |title=Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation |journal=Leukemia |volume=28 |issue=6 |pages=1334–40 |date=June 2014 |pmid=24296945 |doi=10.1038/leu.2013.365 |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" align=center |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
'''Negative'''
* [[CDKN2A]], [[TP53]], JUN, [[JUNB]], [[JUND]], FOS, [[EVI5]]
|-  
|-  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
[[CD23]]
Lymphocyte development and regulation<ref name="pmid24349473">{{cite journal |vauthors=Parry M, Rose-Zerilli MJ, Gibson J, Ennis S, Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier DG, Strefford JC |title=Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma |journal=PLoS ONE |volume=8 |issue=12 |pages=e83244 |date=2013 |pmid=24349473 |pmc=3862727 |doi=10.1371/journal.pone.0083244 |url=}}</ref><ref name="pmid25779943">{{cite journal |vauthors=Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, Parker H, Parker A, Davis Z, Gardiner A, McIver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, de Castro DG, Dearden C, Pratt G, Rosenquist R, Ashton-Key M, Forconi F, Collins A, Ghia P, Matutes E, Pangalis G, Stamatopoulos K, Oscier D, Strefford JC |title=Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing |journal=Clin. Cancer Res. |volume=21 |issue=18 |pages=4174–4183 |date=September 2015 |pmid=25779943 |pmc=4490180 |doi=10.1158/1078-0432.CCR-14-2759 |url=}}</ref><ref name="pmid24296945">{{cite journal |vauthors=Martínez N, Almaraz C, Vaqué JP, Varela I, Derdak S, Beltran S, Mollejo M, Campos-Martin Y, Agueda L, Rinaldi A, Kwee I, Gut M, Blanc J, Oscier D, Strefford JC, Martinez-Lopez J, Salar A, Sole F, Rodriguez-Peralto JL, Diez-Tascón C, García JF, Fraga M, Sebastián E, Alvés J, Menárguez J, González-Carreró J, Casado LF, Bayes M, Bertoni F, Gut I, Piris MA |title=Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation |journal=Leukemia |volume=28 |issue=6 |pages=1334–40 |date=June 2014 |pmid=24296945 |doi=10.1038/leu.2013.365 |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" align=center |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
'''Negative'''
* [[NOTCH1]], [[NOTCH2]], [[SPEN]], [[DTX1]],[[SWAP70]], [[MAML2]], ARIDA3,[[NOTCH3]], NOTCH4, [[PAX5]], MAPK3K8
|-  
|-  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
[[CD43]]
Chromosomal and transcriptional regulation<ref name="pmid25779943">{{cite journal |vauthors=Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, Parker H, Parker A, Davis Z, Gardiner A, McIver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, de Castro DG, Dearden C, Pratt G, Rosenquist R, Ashton-Key M, Forconi F, Collins A, Ghia P, Matutes E, Pangalis G, Stamatopoulos K, Oscier D, Strefford JC |title=Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing |journal=Clin. Cancer Res. |volume=21 |issue=18 |pages=4174–4183 |date=September 2015 |pmid=25779943 |pmc=4490180 |doi=10.1158/1078-0432.CCR-14-2759 |url=}}</ref><ref name="pmid21113978">{{cite journal |vauthors=Rinaldi A, Forconi F, Arcaini L, Mian M, Sozzi E, Zibellini S, Baldini L, Franceschetti S, Gaidano G, Marasca R, Mollejo M, Piris MA, Tucci A, Facchetti F, Bhagat G, Favera RD, Rancoita PM, Zucca E, Kwee I, Bertoni F |title=Immunogenetics features and genomic lesions in splenic marginal zone lymphoma |journal=Br. J. Haematol. |volume=151 |issue=5 |pages=435–9 |date=December 2010 |pmid=21113978 |doi= |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" align=center |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
'''Negative'''
* [[MLL2]], [[MLL3]], [[ARID1A]], [[EP300]], SYMD1, [[HIST1H1D]], [[HIST1H1E]], [[HIST1H2BI]], [[SIN3A]], GPS2, [[BCL6]], [[POT1]]
|-  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=center" |
[[cyclin D1]]
| style="padding: 5px 5px; background: #F5F5F5;" align=center |
''' Negative'''
|}
|}
 
===Associated conditions===
==Microscopic Pathology==
* [[Hepatitis C]] infection
* '''Splenic marginal zone lymphoma''' (SMZL) is a [[lymphoma]] comprised of [[B-cells]] that replace the normal architecture of the [[white pulp]] of the [[spleen]].
** A strong association between [[splenic marginal zone lymphoma]] ([[SMZL]]) and [[hepatitis C]] infection has been observed in several studies indicating that [[viral antigen]] may be involved in the pathogenesis of the lymphoma.<ref name="pmid20530156">{{cite journal |vauthors=Chuang SS, Liao YL, Chang ST, Hsieh YC, Kuo SY, Lu CL, Hwang WS, Lin IH, Tsao CJ, Huang WT |title=Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas |journal=J. Clin. Pathol. |volume=63 |issue=7 |pages=595–8 |date=July 2010 |pmid=20530156 |doi=10.1136/jcp.2010.076810 |url=}}</ref><ref name="pmid17852855">{{cite journal |vauthors=Gurvits GE, Mahtani R, Halperin I |title=Hepatitis C virus and splenic marginal zone lymphoma with villous lymphocytes: away from conventional therapy |journal=Scand. J. Gastroenterol. |volume=42 |issue=11 |pages=1392–3 |date=November 2007 |pmid=17852855 |doi=10.1080/00365520701420800 |url=}}</ref>
* The neoplastic cells are both small [[lymphocytes]] and larger, transformed blasts; and they invade the mantle zone of [[splenic]] [[follicle]]s and erode the [[marginal zone]], ultimately invading the red pulp of the spleen.  
** It is assumed that may be the [[HCV]] [[antigen]] stimulate the [[monoclonal]] [[B-cell proliferation]] through their specific receptor on the cell surface.<ref name="pmid12916862">{{cite journal |vauthors=Weng WK, Levy S |title=Hepatitis C virus (HCV) and lymphomagenesis |journal=Leuk. Lymphoma |volume=44 |issue=7 |pages=1113–20 |date=July 2003 |pmid=12916862 |doi=10.1080/1042819031000076972 |url=}}</ref><ref name="pmid11739181">{{cite journal |vauthors=Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S |title=The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis |journal=Blood |volume=98 |issue=13 |pages=3745–9 |date=December 2001 |pmid=11739181 |doi= |url=}}</ref>
* The neoplastic cells circulating in the peripheral blood are termed villious lymphocytes due to their characteristic appearance.<ref name="who1">[http://www.iarc.fr/WHO-BlueBooks/BBwebsite/bb3.html] Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. (eds): '''World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues.''' IARC Press: Lyon 2001 </ref>
** [[Regression]] of the lymphoma was seen in patients after treatment with [[anti viral]] therapy again suggesting the role of [[viral]] [[antigen]] in its pathogenesis.<ref name="pmid12110736">{{cite journal |vauthors=Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X |title=Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection |journal=N. Engl. J. Med. |volume=347 |issue=2 |pages=89–94 |date=July 2002 |pmid=12110736 |doi=10.1056/NEJMoa013376 |url=}}</ref>
* Other features that may been seen include [[sinus]] invasion, [[epithelial histocytes]], and plasmacytic differentiation of neoplastic cells.
===Microscopic Pathology===
* Aside from the uniform involvement of the [[spleen]], the [[bone marrow]] is frequently positive in patients with splenic marginal zone lymphoma. [[Nodal]] and [[extranodal]] involvement are rare.<ref name="who1"/>
* '''Splenic marginal zone lymphoma''' (SMZL) tends to involve different organs such as [[spleen]], [[bone marrow]], [[blood]] and [[lymph nodes]].<ref name="pmid23233614">{{cite journal |vauthors=Zinzani PL |title=The many faces of marginal zone lymphoma |journal=Hematology Am Soc Hematol Educ Program |volume=2012 |issue= |pages=426–32 |date=2012 |pmid=23233614 |doi=10.1182/asheducation-2012.1.426 |url=}}</ref>.<ref name="pmid26989207">{{cite journal |vauthors=Arcaini L, Rossi D, Paulli M |title=Splenic marginal zone lymphoma: from genetics to management |journal=Blood |volume=127 |issue=17 |pages=2072–81 |date=April 2016 |pmid=26989207 |doi=10.1182/blood-2015-11-624312 |url=}}</ref>
:* Splenic Hilar Lymph Nodes
* The microscopic features of these organs are described below:
::* Involved hilar [[lymph nodes]] adjacent to the [[spleen]] show an effaced architecture without preservation of the [[marginal zone]] seen in the spleen.<ref name="who1"/>  
'''Spleen'''
:* Bone Marrow Biopsy
*  Micronodular pattern of [[lymphocytic]] infiltration of the [[white pulp]] involving both mantle and marginal zone component.<ref name="pmid17325486">{{cite journal |vauthors=Papadaki T, Stamatopoulos K, Belessi C, Pouliou E, Parasi A, Douka V, Laoutaris N, Fassas A, Anagnostopoulos A, Anagnostou D |title=Splenic marginal-zone lymphoma: one or more entities? A histologic, immunohistochemical, and molecular study of 42 cases |journal=Am. J. Surg. Pathol. |volume=31 |issue=3 |pages=438–46 |date=March 2007 |pmid=17325486 |doi=10.1097/01.pas.0000213419.08009.b0 |url=}}</ref>
::* Splenic marginal zone lymphoma in [[bone marrow]] displays a nodular pattern with morphology similar to what is observed in the splenic [[hilar]] [[lymph nodes]].<ref name="fra1"> [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8971565&query_hl=13&itool=pubmed_ExternalLink]
* [[Biphasic]] distribution of  neoplastic B-cell in the follicles i.e small cells having dense chromatin and scant [[cytoplasm]] surrounded by intermediate size cells of marginal zone having variable nuclear contour and relatively abundant [[cytoplasm]] with interspersed large B-cells.
Franco V, Florena AM, Campesi G. "Intrasinusoidal bone marrow infiltration: a possible hallmark of splenic lymphoma." '''Histopathology'''. 1996 Dec;29(6):571-5. PMID: 8971565</ref>
* [[Red pulp]] may also be involved either sparingly or diffusely penetrating the sinuses and cords.<ref name="pmid11903595">{{cite journal |vauthors=Mollejo M, Algara P, Mateo MS, Sánchez-Beato M, Lloret E, Medina MT, Piris MA |title=Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma? |journal=Histopathology |volume=40 |issue=1 |pages=22–30 |date=January 2002 |pmid=11903595 |doi= |url=}}</ref>
'''Bone Marrow''':
* Various patterns of [[Lymphocytic]] infiltration such as intrasinusoidal, [[nodular]], [[interstitial]] and [[intravascular]] have been observed.<ref name="pmid28892912">{{cite journal |vauthors=Mohanpuria A, Kumar V, Suteri P, Marwah S, Nigam AS |title=Important Diagnostic Clues for Diagnosing Splenic Marginal Zone Lymphoma in Absence of Splenic Histology |journal=J Clin Diagn Res |volume=11 |issue=7 |pages=ED15–ED17 |date=July 2017 |pmid=28892912 |pmc=5583942 |doi=10.7860/JCDR/2017/27149.10190 |url=}}</ref>
* Mixed pattern of [[lymphocytic]] infiltration with intrasinusoidal being predominant.<ref name="pmid15389479">{{cite journal |vauthors=Iannitto E, Ambrosetti A, Ammatuna E, Colosio M, Florena AM, Tripodo C, Minardi V, Calvaruso G, Mitra ME, Pizzolo G, Menestrina F, Franco V |title=Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients |journal=Cancer |volume=101 |issue=9 |pages=2050–7 |date=November 2004 |pmid=15389479 |doi=10.1002/cncr.20596 |url=}}</ref><ref name="pmid12090417">{{cite journal |vauthors=Kent SA, Variakojis D, Peterson LC |title=Comparative study of marginal zone lymphoma involving bone marrow |journal=Am. J. Clin. Pathol. |volume=117 |issue=5 |pages=698–708 |date=May 2002 |pmid=12090417 |doi=10.1309/MECJ-GLK1-WEBW-UEVE |url=}}</ref>
* Cell population consists of small, intermediate and large [[lymphoid]] cells but small cells having large [[nucleus]] with dense [[chromatin]] and scant [[cytoplasm]] are present in abundance.<ref name="pmid23073320">{{cite journal |vauthors=Ponzoni M, Kanellis G, Pouliou E, Baliakas P, Scarfò L, Ferreri AJ, Doglioni C, Bikos V, Dagklis A, Anagnostopoulos A, Ghia P, Stamatopoulos K, Papadaki T |title=Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology? |journal=Am. J. Surg. Pathol. |volume=36 |issue=11 |pages=1609–18 |date=November 2012 |pmid=23073320 |doi=10.1097/PAS.0b013e318271243d |url=}}</ref>
'''Lymph nodes'''
* Splenic [[hilar]] and [[peripheral]] [[lymph nodes]] may be involved but less frequently as compared to the other organs.
* Micronodular infiltration with no involvement of the [[sinuses]].<ref name="pmid9236833">{{cite journal |vauthors=Mollejo M, Lloret E, Menárguez J, Piris MA, Isaacson PG |title=Lymph node involvement by splenic marginal zone lymphoma: morphological and immunohistochemical features |journal=Am. J. Surg. Pathol. |volume=21 |issue=7 |pages=772–80 |date=July 1997 |pmid=9236833 |doi= |url=}}</ref>
'''Blood'''
* Unusual [[neoplastic]] [[lymphoid]] B-cells with irregular [[cytoplasmic]] processes.<ref name="pmid534161">{{cite journal |vauthors=Wolfe JM |title=The computer paper illusion |journal=Perception |volume=8 |issue=3 |pages=347–8 |date=1979 |pmid=534161 |doi=10.1068/p080347 |url=}}</ref>


==References==
==References==
Line 74: Line 86:


[[Category:Disease]]
[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Immunology]]

Latest revision as of 21:30, 30 January 2019

Splenic marginal zone lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Splenic marginal zone lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Splenic marginal zone lymphoma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Splenic marginal zone lymphoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Splenic marginal zone lymphoma pathophysiology

CDC on Splenic marginal zone lymphoma pathophysiology

Splenic marginal zone lymphoma pathophysiology in the news

Blogs on Splenic marginal zone lymphoma pathophysiology

Directions to Hospitals Treating Splenic marginal zone lymphoma

Risk calculators and risk factors for Splenic marginal zone lymphoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Muhammad Affan M.D.[4], Sowminya Arikapudi, M.B,B.S. [5]

Overview

The exact pathogenesis of splenic marginal zone lymphoma (SMZL) is not clearly understood but according to some studies chronic immunologic stimulation and certain gene mutations are assumed to be involved. The common chromosomal aberrations and genetic mutations in splenic marginal zone lymphoma (SMZL) includes 7q32 deletion, gain of function mutation in 3q and NOTCH2, TP53, KLF2 gene mutations. These genes control certain cell regulation pathways that are involved in normal functioning of the cell. Hepatitis C viral antigen has also been assumed to be involved in its pathogenesis. Spleen, bone marrow, lymph nodes, liver and blood may be infiltrated with the tumor and have certain distintive features. On microscopic histopathological analysis, B-cells, villous lymphocytes, and sinus invasion are characteristic findings of splenic marginal zone lymphoma (SMZL).

Pathophysiology

Pathogenesis

Genetics

  • There are several pathways involved in the normal functioning of the cells. Genetic dysregulation may affect these pathways resulting in abnormal function.
  • Common genetic abnormalities and their affected pathways in splenic marginal zone lymphoma are summarized under:
Pathways Gene mutations

NFkB[24][25][19]

Apoptosis[26][27]

Cell communication[28][29][30]

Cell cycle control[15][27][30]

Lymphocyte development and regulation[28][25][30]

Chromosomal and transcriptional regulation[25][31]

Associated conditions

Microscopic Pathology

Spleen

  • Micronodular pattern of lymphocytic infiltration of the white pulp involving both mantle and marginal zone component.[39]
  • Biphasic distribution of neoplastic B-cell in the follicles i.e small cells having dense chromatin and scant cytoplasm surrounded by intermediate size cells of marginal zone having variable nuclear contour and relatively abundant cytoplasm with interspersed large B-cells.
  • Red pulp may also be involved either sparingly or diffusely penetrating the sinuses and cords.[40]

Bone Marrow:

Lymph nodes

Blood

References

  1. ↑ Fonte E, Agathangelidis A, Reverberi D, Ntoufa S, Scarfò L, Ranghetti P, Cutrona G, Tedeschi A, Xochelli A, Caligaris-Cappio F, Ponzoni M, Belessi C, Davis Z, Piris MA, Oscier D, Ghia P, Stamatopoulos K, Muzio M (November 2015). "Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation". Haematologica. 100 (11): 1460–8. doi:10.3324/haematol.2014.119933. PMC 4825289. PMID 26294727.
  2. ↑ Franco G, Guarnotta C, Frossi B, Piccaluga PP, Boveri E, Gulino A, Fuligni F, Rigoni A, Porcasi R, Buffa S, Betto E, Florena AM, Franco V, Iannitto E, Arcaini L, Pileri SA, Pucillo C, Colombo MP, Sangaletti S, Tripodo C (March 2014). "Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma". Blood. 123 (12): 1836–49. doi:10.1182/blood-2013-04-497271. PMID 24452203.
  3. ↑ Dunn-Walters DK, Boursier L, Spencer J, Isaacson PG (June 1998). "Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation". Hum. Pathol. 29 (6): 585–93. PMID 9635678.
  4. ↑ Miranda RN, Cousar JB, Hammer RD, Collins RD, Vnencak-Jones CL (March 1999). "Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy cell leukemia are composed of memory B lymphocytes". Hum. Pathol. 30 (3): 306–12. PMID 10088550.
  5. ↑ Tierens A, Delabie J, Pittaluga S, Driessen A, DeWolf-Peeters C (April 1998). "Mutation analysis of the rearranged immunoglobulin heavy chain genes of marginal zone cell lymphomas indicates an origin from different marginal zone B lymphocyte subsets". Blood. 91 (7): 2381–6. PMID 9516137.
  6. ↑ Camacho FI, Mollejo M, Mateo MS, Algara P, Navas C, Hernández JM, Santoja C, Solé F, Sánchez-Beato M, Piris MA (October 2001). "Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases". Am. J. Surg. Pathol. 25 (10): 1268–76. PMID 11688461.
  7. ↑ Stevenson F, Sahota S, Zhu D, Ottensmeier C, Chapman C, Oscier D, Hamblin T (April 1998). "Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes". Immunol. Rev. 162: 247–59. PMID 9602369.
  8. ↑ Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (May 2011). "The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications". Blood. 117 (19): 5019–32. doi:10.1182/blood-2011-01-293050. PMC 3109529. PMID 21300984.
  9. ↑ Spencer J, Perry ME, Dunn-Walters DK (September 1998). "Human marginal-zone B cells". Immunol. Today. 19 (9): 421–6. PMID 9745206.
  10. ↑ Timens W, Poppema S (September 1985). "Lymphocyte compartments in human spleen. An immunohistologic study in normal spleens and uninvolved spleens in Hodgkin's disease". Am. J. Pathol. 120 (3): 443–54. PMC 1887979. PMID 3898859.
  11. ↑ [1] Dunn-Walters DK, Boursier L, Spencer J, Isaacson PG. "Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation." Hum Pathol. 1998 Jun;29(6):585-93. PMID: 9635678
  12. ↑ Boonstra R, Bosga-Bouwer A, van Imhoff GW, Krause V, Palmer M, Coupland RW, Dabbagh L, van den Berg E, van den Berg A, Poppema S (December 2003). "Splenic marginal zone lymphomas presenting with splenomegaly and typical immunophenotype are characterized by allelic loss in 7q31-32". Mod. Pathol. 16 (12): 1210–7. doi:10.1097/01.MP.0000095895.19756.77. PMID 14681321.
  13. ↑ Hernández JM, García JL, Gutiérrez NC, Mollejo M, Martínez-Climent JA, Flores T, González MB, Piris MA, San Miguel JF (May 2001). "Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics". Am. J. Pathol. 158 (5): 1843–50. doi:10.1016/S0002-9440(10)64140-5. PMC 1891967. PMID 11337382.
  14. ↑ Andersen CL, Gruszka-Westwood A, Atkinson S, Matutes E, Catovsky D, Pedersen RK, Pedersen BB, Pulczynski S, Hokland P, Jacobsen E, Koch J (January 2005). "Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization". Cancer Genet. Cytogenet. 156 (2): 122–8. doi:10.1016/j.cancergencyto.2004.04.026. PMID 15642391.
  15. ↑ 15.0 15.1 Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luño E, Wlodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Solé F (September 2010). "Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group". Blood. 116 (9): 1479–88. doi:10.1182/blood-2010-02-267476. PMID 20479288.
  16. ↑ Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G (August 2012). "The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development". J. Exp. Med. 209 (9): 1537–51. doi:10.1084/jem.20120904. PMID 22891273.
  17. ↑ Trøen G, Wlodarska I, Warsame A, Hernández Llodrà S, De Wolf-Peeters C, Delabie J (July 2008). "NOTCH2 mutations in marginal zone lymphoma". Haematologica. 93 (7): 1107–9. doi:10.3324/haematol.11635. PMID 18508802.
  18. ↑ Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Bruscaggin A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri SA, Foà R, Inghirami G, Gaidano G, Rossi D (February 2015). "The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma". Leukemia. 29 (2): 503–7. doi:10.1038/leu.2014.294. PMID 25283840.
  19. ↑ 19.0 19.1 Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Bruscaggin A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I, Pileri SA, Foà R, Bertoni F, Dalla-Favera R, Pasqualucci L, Gaidano G (November 2011). "Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma". Blood. 118 (18): 4930–4. doi:10.1182/blood-2011-06-359166. PMID 21881048.
  20. ↑ Spina V, Rossi D (August 2016). "NF-κB deregulation in splenic marginal zone lymphoma". Semin. Cancer Biol. 39: 61–7. doi:10.1016/j.semcancer.2016.08.002. PMID 27503810.
  21. ↑ Baldini L, Fracchiolla NS, Cro LM, Trecca D, Romitti L, Polli E, Maiolo AT, Neri A (July 1994). "Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin". Blood. 84 (1): 270–8. PMID 8018922.
  22. ↑ Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D (June 2001). "p53 abnormalities in splenic lymphoma with villous lymphocytes". Blood. 97 (11): 3552–8. PMID 11369650.
  23. ↑ [2] Corcoran MM, Mould SJ, Orchard JA, Ibbotson RE, Chapman RM, Boright AP, Platt C, Tsui LC, Scherer SW, Oscier DG. "Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations." Oncogene. 1999 Nov 4;18(46):6271-7. PMID: 10597225
  24. ↑ Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G, Bolli N, Grove C, Moody S, Escudero-Ibarz L, Gundem G, Brugger K, Xue X, Mi E, Bench A, Scott M, Liu H, Follows G, Robles EF, Martinez-Climent JA, Oscier D, Watkins AJ, Du MQ (May 2015). "KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype". Leukemia. 29 (5): 1177–85. doi:10.1038/leu.2014.330. PMID 25428260.
  25. ↑ 25.0 25.1 25.2 Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, Parker H, Parker A, Davis Z, Gardiner A, McIver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, de Castro DG, Dearden C, Pratt G, Rosenquist R, Ashton-Key M, Forconi F, Collins A, Ghia P, Matutes E, Pangalis G, Stamatopoulos K, Oscier D, Strefford JC (September 2015). "Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing". Clin. Cancer Res. 21 (18): 4174–4183. doi:10.1158/1078-0432.CCR-14-2759. PMC 4490180. PMID 25779943.
  26. ↑ Ruiz-Ballesteros E, Mollejo M, Rodriguez A, Camacho FI, Algara P, Martinez N, Pollán M, Sanchez-Aguilera A, Menarguez J, Campo E, Martinez P, Mateo M, Piris MA (September 2005). "Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis". Blood. 106 (5): 1831–8. doi:10.1182/blood-2004-10-3898. PMID 15914563.
  27. ↑ 27.0 27.1 Trøen G, Nygaard V, Jenssen TK, Ikonomou IM, Tierens A, Matutes E, Gruszka-Westwood A, Catovsky D, Myklebost O, Lauritzsen G, Hovig E, Delabie J (November 2004). "Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma". J Mol Diagn. 6 (4): 297–307. doi:10.1016/S1525-1578(10)60525-9. PMC 1867488. PMID 15507668.
  28. ↑ 28.0 28.1 Parry M, Rose-Zerilli MJ, Gibson J, Ennis S, Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier DG, Strefford JC (2013). "Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma". PLoS ONE. 8 (12): e83244. doi:10.1371/journal.pone.0083244. PMC 3862727. PMID 24349473.
  29. ↑ Fresquet V, Robles EF, Parker A, Martinez-Useros J, Mena M, Malumbres R, Agirre X, Catarino S, Arteta D, Osaba L, Mollejo M, Hernandez-Rivas JM, Calasanz MJ, Daibata M, Dyer MJ, Prosper F, Vizcarra E, Piris MÁ, Oscier D, Martinez-Climent JA (September 2012). "High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma". Br. J. Haematol. 158 (6): 712–26. doi:10.1111/j.1365-2141.2012.09226.x. PMID 22816737.
  30. ↑ 30.0 30.1 30.2 Martínez N, Almaraz C, Vaqué JP, Varela I, Derdak S, Beltran S, Mollejo M, Campos-Martin Y, Agueda L, Rinaldi A, Kwee I, Gut M, Blanc J, Oscier D, Strefford JC, Martinez-Lopez J, Salar A, Sole F, Rodriguez-Peralto JL, Diez-Tascón C, García JF, Fraga M, Sebastián E, Alvés J, Menárguez J, González-Carreró J, Casado LF, Bayes M, Bertoni F, Gut I, Piris MA (June 2014). "Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation". Leukemia. 28 (6): 1334–40. doi:10.1038/leu.2013.365. PMID 24296945.
  31. ↑ Rinaldi A, Forconi F, Arcaini L, Mian M, Sozzi E, Zibellini S, Baldini L, Franceschetti S, Gaidano G, Marasca R, Mollejo M, Piris MA, Tucci A, Facchetti F, Bhagat G, Favera RD, Rancoita PM, Zucca E, Kwee I, Bertoni F (December 2010). "Immunogenetics features and genomic lesions in splenic marginal zone lymphoma". Br. J. Haematol. 151 (5): 435–9. PMID 21113978.
  32. ↑ Chuang SS, Liao YL, Chang ST, Hsieh YC, Kuo SY, Lu CL, Hwang WS, Lin IH, Tsao CJ, Huang WT (July 2010). "Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas". J. Clin. Pathol. 63 (7): 595–8. doi:10.1136/jcp.2010.076810. PMID 20530156.
  33. ↑ Gurvits GE, Mahtani R, Halperin I (November 2007). "Hepatitis C virus and splenic marginal zone lymphoma with villous lymphocytes: away from conventional therapy". Scand. J. Gastroenterol. 42 (11): 1392–3. doi:10.1080/00365520701420800. PMID 17852855.
  34. ↑ Weng WK, Levy S (July 2003). "Hepatitis C virus (HCV) and lymphomagenesis". Leuk. Lymphoma. 44 (7): 1113–20. doi:10.1080/1042819031000076972. PMID 12916862.
  35. ↑ Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S (December 2001). "The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis". Blood. 98 (13): 3745–9. PMID 11739181.
  36. ↑ Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X (July 2002). "Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection". N. Engl. J. Med. 347 (2): 89–94. doi:10.1056/NEJMoa013376. PMID 12110736.
  37. ↑ Zinzani PL (2012). "The many faces of marginal zone lymphoma". Hematology Am Soc Hematol Educ Program. 2012: 426–32. doi:10.1182/asheducation-2012.1.426. PMID 23233614.
  38. ↑ Arcaini L, Rossi D, Paulli M (April 2016). "Splenic marginal zone lymphoma: from genetics to management". Blood. 127 (17): 2072–81. doi:10.1182/blood-2015-11-624312. PMID 26989207.
  39. ↑ Papadaki T, Stamatopoulos K, Belessi C, Pouliou E, Parasi A, Douka V, Laoutaris N, Fassas A, Anagnostopoulos A, Anagnostou D (March 2007). "Splenic marginal-zone lymphoma: one or more entities? A histologic, immunohistochemical, and molecular study of 42 cases". Am. J. Surg. Pathol. 31 (3): 438–46. doi:10.1097/01.pas.0000213419.08009.b0. PMID 17325486.
  40. ↑ Mollejo M, Algara P, Mateo MS, Sánchez-Beato M, Lloret E, Medina MT, Piris MA (January 2002). "Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma?". Histopathology. 40 (1): 22–30. PMID 11903595.
  41. ↑ Mohanpuria A, Kumar V, Suteri P, Marwah S, Nigam AS (July 2017). "Important Diagnostic Clues for Diagnosing Splenic Marginal Zone Lymphoma in Absence of Splenic Histology". J Clin Diagn Res. 11 (7): ED15–ED17. doi:10.7860/JCDR/2017/27149.10190. PMC 5583942. PMID 28892912.
  42. ↑ Iannitto E, Ambrosetti A, Ammatuna E, Colosio M, Florena AM, Tripodo C, Minardi V, Calvaruso G, Mitra ME, Pizzolo G, Menestrina F, Franco V (November 2004). "Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients". Cancer. 101 (9): 2050–7. doi:10.1002/cncr.20596. PMID 15389479.
  43. ↑ Kent SA, Variakojis D, Peterson LC (May 2002). "Comparative study of marginal zone lymphoma involving bone marrow". Am. J. Clin. Pathol. 117 (5): 698–708. doi:10.1309/MECJ-GLK1-WEBW-UEVE. PMID 12090417.
  44. ↑ Ponzoni M, Kanellis G, Pouliou E, Baliakas P, Scarfò L, Ferreri AJ, Doglioni C, Bikos V, Dagklis A, Anagnostopoulos A, Ghia P, Stamatopoulos K, Papadaki T (November 2012). "Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?". Am. J. Surg. Pathol. 36 (11): 1609–18. doi:10.1097/PAS.0b013e318271243d. PMID 23073320.
  45. ↑ Mollejo M, Lloret E, Menárguez J, Piris MA, Isaacson PG (July 1997). "Lymph node involvement by splenic marginal zone lymphoma: morphological and immunohistochemical features". Am. J. Surg. Pathol. 21 (7): 772–80. PMID 9236833.
  46. ↑ Wolfe JM (1979). "The computer paper illusion". Perception. 8 (3): 347–8. doi:10.1068/p080347. PMID 534161.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Splenic_marginal_zone_lymphoma_pathophysiology&oldid=1543741"